Akari Therapeutics (AKTX) Stock Skyrockets 120% on Promising Cancer Drug Results

Table of Contents Akari Therapeutics (AKTX) experienced a dramatic 120% surge during after-hours trading Thursday following the release of encouraging preclinical findings for AKTX-101, its primary drug candidate targeting difficult-to-treat pancreatic malignancies. Akari Therapeutics, Plc, AKTX The compound—an antibody-drug conjugate (ADC) designed to bind to the Trop2 receptor—underwent evaluation in combination with adagrasib, an inhibitor of KRAS. The findings were unveiled through an ASCO abstract. When tested in pancreatic cancer cell cultures harboring KRAS G12C and G12D mutations, the combination of AKTX-101 and adagrasib generated synergistic tumor cell destruction. This indicates the dual therapy delivered superior results compared to either agent administered independently. The standout aspect of these results lies in the contrasting behavior observed with competing therapies. First-generation topoisomerase I-targeting TROP2 ADCs exhibited antagonism—the opposite of synergy—when combined with adagrasib. The synergistic properties of AKTX-101 stem from its innovative RNA spliceosome-modulating payload, designated PH1. According to Akari, PH1 operates by marking pre-mRNA transcripts for destruction, including those harboring KRAS mutations responsible for driving these cancers. This represents a distinctly different mode of action compared to most existing TROP2 ADCs. Pancreatic cancer driven by KRAS mutations has historically represented one of the most challenging obstacles in cancer treatment. These findings suggest that RNA splicing modulation could offer a promising therapeutic approach—and that AKTX-101’s unique payload differentiates it significantly from competing compounds. The biotech company indicated these results broaden the commercial potential for AKTX-101 beyond its currently planned Phase 1 development program. Akari has commenced IND-enabling preclinical studies and aims to launch a Phase 1 first-in-human clinical trial by the middle of 2027. The company’s pipeline also includes AKTX-102, a second ADC candidate targeting CEACAM5, a well-established tumor antigen. Development of this program remains at an earlier stage. Akari operates as an extremely small biotechnology company. With a market capitalization of merely $5.77 million, it falls squarely into micro-cap territory. This size explains the magnitude of the price movement; relatively limited trading volume can generate substantial percentage swings. Regulatory filings show four insider purchases during the trailing twelve months, with zero insider sales recorded. While modest, this pattern suggests some degree of internal conviction. AKTX carries a GF Score of only 22 out of 100, with profitability metrics scoring just 1 out of 10. The company generates no revenue and operates at a loss, characteristics standard for clinical-stage biotechnology firms. Despite Thursday’s impressive after-hours rally, AKTX shares remain down approximately 55% year-to-date. The stock had experienced persistent downward pressure prior to this data release. With the Phase 1 trial scheduled for mid-2027, investors face a considerable waiting period before any human efficacy data becomes available.